Neurology & CNS Deal Benchmarks
Deal benchmarks for Alzheimer's, Parkinson's, epilepsy, migraine, schizophrenia, and other neurological disorders. Benchmarks derived from 298 verified transactions.
298
Total Deals
$235M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
87
license
105
acquisition
72
collaboration
12
option
15
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Corium Therapeutics → Collegium Pharmaceutical Azstarys | acquisition | $650M | $785M | Mar 2026 |
Alcyone Therapeutics → Biogen ThecaFlex DRx implant | acquisition | $85M | $85M | Mar 2026 |
Sangamo Therapeutics → Eli Lilly STAC-BBB AAV capsid | license | $18M | $1.4B | Mar 2026 |
Verve Therapeutics → Eli Lilly neurological gene-editing therapies | acquisition | $1.3B | $1.3B | Mar 2026 |
Zevra Therapeutics → Commave Therapeutics SA serdexmethylphenidate (SDX) portfolio | acquisition | $50M | $50M | Mar 2026 |
Rapport Therapeutics → Tenacia Biotechnology RAP-219 | license | $20M | $328M | Mar 2026 |
Rapport Therapeutics Inc. → Tenacia Biotechnology Co. Ltd. RAP-219 | license | $20M | $328M | Mar 2026 |
Rapport Therapeutics, Inc. → Tenacia Biotechnology (Hong Kong) Co., Ltd RAP-219 | license | $20M | $328M | Mar 2026 |
Rapport Therapeutics → Tenacia Biotechnology RAP-219 | license | $20M | $328M | Mar 2026 |
SciNeuro → Novartis amyloid beta-targeted antibody program with BBB shuttle | license | $165M | — | Jan 2026 |
Benchmark Your Neurology & CNS Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 298 verified neurology & cns transactions.
Run Neurology & CNS Benchmark